Effect of long‐term prophylaxis in the development of cytomegalovirus‐specific T‐cell immunity in D+/R− solid organ transplant recipients

Abstract

The rate of acquisition of CMV-specific CMI in SOT recipients undergoing antiviral prophylaxis differed significantly between different SOT populations. Patients developing any detectable CMI response were protected against the occurrence of CMV disease.

Cytomegalovirus infection in heart transplantation: A single center experience

“…One avenue to next evaluate is that of a subsequent preemptive strategy (a so‐called “hybrid” approach) . This defined post‐prophylaxis period of risk for CMV infection may also guide emerging diagnostic strategies such interferon‐gamma release assays and consideration of other preemptive interventions such as CMV immunoglobulin …”

Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis

“…6,7 To account for the difference in time to infection following VGC prophylaxis among CMV risk cohorts, we considered a number of possibilities, including the role of CMV-specific CMI in preventing CMV infection and disease following SOT. [20][21][22] In a study of 95…”

Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients

“…Cytomegalovirus pp65 and IE-1-specific IFN-γ CD8 + T cells were enumerated by flow cytometry for intracellular cytokine staining (BD Fastimmune, BD Becton Dickinson and Company, and BD Biosciences, San Jose, CA) as previously reported [ 19 , 20 ]. Whole blood (0.5 mL) was simultaneously stimulated for 6 hours with 2 sets of 15-mer overlapping peptides encompassing the entire sequence of pp65 and IE-1 CMV proteins (1 μg/mL per peptide) obtained from JPT Peptide Technologies GmbH (Berlin, Germany), in the presence of l μg/mL of costimulatory monoclonal antibodies to CD28 and CD49d.…”